Placebo News and Research

RSS

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.

1 Nov 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Anadys Pharmaceuticals, Inc. today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.

1 Nov 2010

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

OptiNose Inc. announced the results from an analysis comparing the Phase II clinical trial obtained with its novel delivery technology to that of other formulations. The analysis suggests rapid absorption rate alone may not explain the efficacy in migraines treated with sumatriptan delivered with the Company's novel bi-directional technology. The results will be presented at the 2nd European Headache and Migraine Trust International on 28th of October 2010.

30 Oct 2010

CONCERTA improves handwriting performance in children with ADHD: Study

Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.

30 Oct 2010

FDA approves NUEDEXTA capsules for pseudobulbar affect

AVANIR Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.

30 Oct 2010

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

MAP Pharmaceuticals, Inc. today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.

29 Oct 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Shire plc the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.

29 Oct 2010

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced top-line results from ACCORD COPD II, a 12-week Phase III study comparing the efficacy and safety of inhaled aclidinium bromide, an investigative bronchodilator, to placebo in 544 patients with moderate to severe COPD.

29 Oct 2010

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Pfizer Inc announced that the Japanese Ministry of Health, Labour and Welfare approved Lyrica (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment of postherpetic neuralgia on April 16, 2010. Lyrica is the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd.

29 Oct 2010

Latuda tablets receive FDA approval for treatment of adults with schizophrenia

The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the treatment of adults with schizophrenia.

29 Oct 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2010.

29 Oct 2010

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

Pharmasset, Inc. reported positive preliminary results today from its phase I monotherapy trial of PSI-352938 for the treatment of chronic hepatitis C (HCV). PSI-938 is a guanosine nucleotide analog polymerase inhibitor in development for the treatment of chronic HCV infection.

28 Oct 2010

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

ChemoCentryx, Inc., today announced that it reported one-year results from the Company's PROTECT-1 Study (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN™ (CCX282-B) in patients with moderate-to-severe Crohn's disease. Traficet-EN, an orally bioavailable CCR9-specific chemokine receptor antagonist showed clinical efficacy in a 12-week Induction period, as well as a 36-week Maintenance period.

28 Oct 2010

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).

28 Oct 2010

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained an initial draft report of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON (OX1).

27 Oct 2010

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

Study finds anti-obesity drug reduces brain’s response to appetizing foods

Scientists have revealed that an anti-obesity drug changes the way the brain responds to appetising, high-calorie foods in obese individuals. This insight may aid the development of new anti-obesity drugs which reduce the activity in the regions of the brain stimulated by the sight of tasty foods.

27 Oct 2010

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a 4 week Phase 1 trial of its new self-applied ViaDerm-hPTH(1-34) for the treatment of osteoporosis.

26 Oct 2010

Placebo News and Research

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

OptiNose presents sumatriptan Phase II trial results at 2nd European Headache and Migraine Trust International

CONCERTA improves handwriting performance in children with ADHD: Study

FDA approves NUEDEXTA capsules for pseudobulbar affect

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Forest, Almirall report topline results from aclidinium bromide comparative Phase III study in COPD

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Latuda tablets receive FDA approval for treatment of adults with schizophrenia

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Intellect obtains initial draft report of OXIGON Phase 1b clinical trial for Alzheimer’s disease

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

Study finds anti-obesity drug reduces brain’s response to appetizing foods

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News